Apellis Pharmaceuticals Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Apellis Pharmaceuticals.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Tuesday, April, 27th. The company reported ($2.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.69) by $0.63.
View Apellis Pharmaceuticals' earnings history.

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APLS shares have increased by 141.6% and is now trading at $65.79.
View which stocks have been most impacted by COVID-19.

12 brokerages have issued 1 year price targets for Apellis Pharmaceuticals' stock. Their forecasts range from $39.00 to $130.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $80.42 in the next year. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Apellis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Viatris (VTRS), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Zai Lab (ZLAB), Maravai LifeSciences (MRVI), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC) and Teva Pharmaceutical Industries (TEVA).
View all of APLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Compagnie Lombard Odier SCmA (0.01%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals.

APLS stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, Pascal Deschatelets, and Victoria L Brown.
View insider buying and selling activity for Apellis Pharmaceuticals or view top insider-selling stocks.

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLS stock can currently be purchased for approximately $65.79.

Apellis Pharmaceuticals has a market capitalization of $5.30 billion and generates $250.65 million in revenue each year. The company earns $-344,870,000.00 in net income (profit) each year or ($4.59) on an earnings per share basis.

Apellis Pharmaceuticals employs 374 workers across the globe.

The official website for Apellis Pharmaceuticals is www.apellis.com.

Apellis Pharmaceuticals is headquartered at 100 FIFTH AVENUE, WALTHAM MA, 02451.

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at (617) 977-5700 or via email at [email protected]